ModerateDirect oral anticoagulants (factor Xa inhibitors)×Other opioids
Updated · Methodology
Mechanism
Rivaroxaban is a direct inhibitor of clotting factor Xa, and drugs that themselves affect haemostasis add to its bleeding risk (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4 and 5.1; rivaroxaban label, US Food and Drug Administration, FDA, section 5.2). The rivaroxaban documents list serotonin and noradrenaline reuptake inhibitors (SNRIs) among these drugs. With SNRIs, the bleeding risk may be higher because of their reported effect on platelets. In the rivaroxaban clinical programme, numerically higher rates of major or clinically relevant non-major bleeding were seen in all treatment groups when SNRIs were used together with rivaroxaban (EMA, sections 4.4 and 4.5; FDA, section 5.2). Tramadol is an opioid that, according to its US label, also weakly inhibits the reuptake of serotonin and noradrenaline (tramadol FDA label, sections 5.7 and 12.1). The documents do not address the combination of rivaroxaban and tramadol directly. The tramadol documents discuss bleeding only in connection with warfarin and other coumarins (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The documents also say nothing about either drug changing the levels of the other. CYP3A4 and CYP2J2 metabolise rivaroxaban, and in vitro it is a substrate of the transporters P-glycoprotein (P-gp) and BCRP. Tramadol is not listed among strong inhibitors or inducers of these pathways. Rivaroxaban itself neither inhibits nor induces the major CYP isoforms, including CYP3A4, which metabolises tramadol together with CYP2D6 (EMA, sections 4.5 and 5.2; AEMPS, section 5.2).
Symptoms
The documents describe no symptoms linked to this combination. The main risk of rivaroxaban is bleeding. In studies, nosebleeds (4.5%) and gastrointestinal bleeding (3.8%) were the most frequent. Rivaroxaban may increase the risk of occult or overt bleeding in any tissue or organ, which can lead to anaemia. The signs and severity depend on the site and extent of bleeding, and the outcome can be fatal (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.8; rivaroxaban label, US Food and Drug Administration, FDA, section 5.2). The most frequent adverse effects of tramadol are nausea and dizziness, seen in more than 10% of patients. Headache, drowsiness, constipation, dry mouth, vomiting and sweating are common (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.8).
Management
The documents do not address this combination directly. According to the rivaroxaban SmPC, rivaroxaban is used with caution together with drugs that affect haemostasis, including serotonin and noradrenaline reuptake inhibitors (SNRIs) (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.4). Tramadol, according to its US label, weakly inhibits the reuptake of serotonin and noradrenaline (tramadol label, US Food and Drug Administration, FDA, section 5.7). The combination is therefore managed with the same caution. People taking rivaroxaban are monitored closely for signs of bleeding, and rivaroxaban is stopped if severe bleeding occurs (EMA, section 4.4). An unexplained fall in haemoglobin or blood pressure calls for a search for a bleeding site. When appropriate, haemoglobin and haematocrit tests may help to detect occult bleeding (EMA, section 4.4). Any signs or symptoms of blood loss are evaluated promptly (rivaroxaban FDA label, section 5.2). The documents give no reason to change the rivaroxaban dose. The rivaroxaban restrictions apply to strong inhibitors of CYP3A4 and P-glycoprotein (P-gp) and to strong CYP3A4 inducers, and tramadol is not listed among them (EMA, sections 4.4 and 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Xarelto (rivaroxabán) – ficha técnica en CIMA (2026)– AEMPS CIMA, Xarelto 20 mg comprimidos recubiertos con película, nº registro 08472018 (EU/1/08/472), secciones 4.3, 4.4 y 4.5
- FDA: Xarelto (rivaroxaban) prescribing information (2026)– FDA label, DailyMed setid 10db92f9-2300-4a80-836b-673e1ae91610, version 65, revised 09/2026, sections 5.2 and 7
- FDA: Tramadol hydrochloride tablets prescribing information (Amneal) (2026)– FDA label, Amneal Pharmaceuticals NY LLC, DailyMed setid 8ec4e4e5-a56e-4198-8428-6b770b9bf27d, revised 06/2026, sections 4, 5.9, 5.10, 7 and 17
- AEMPS: Ficha técnica: Tramadol, Adolonta 50 mg cápsulas (nº registro 59088), sección 4.5 (2025)– AEMPS, CIMA, nº registro 59088, revisión 11/2025, secciones 4.2, 4.4 y 4.5